Subscribe To
Biocardia (bcda) up on plans for second heart failure study
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its cardiamp cell therapy for the...
October 12, 2023, 12:47 pm
Biocardia (bcda) dips 26% on flunking heart failure study
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its cardiamp...
September 6, 2023, 12:01 pm
Biocardia announces interim efficacy results in phase iii pivotal cardiamp cell therapy heart failure trial
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
September 5, 2023, 11:15 am
Biocardia shares slide on disappointing interim data from heart therapy trial
BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of ...
September 5, 2023, 9:31 am
Biocardia announces fda completes review of proposed adaptive statistical analysis design for ongoing cardiamp cell therapy in heart failure pivotal study
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the ...
June 20, 2023, 9:14 pm
Biocardia announces timing of the next data safety monitoring board meeting for the cardiamp cell therapy in heart failure pivotal study
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the t...
May 23, 2023, 11:00 am
Safety board recommends biocardia's heart failure cell therapy to continue unchanged
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...
February 14, 2022, 10:29 am
Safety board recommends biocardia's heart failure cell therapy to continue unchanged
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...
February 14, 2022, 10:29 am
Safety board recommends biocardia's heart failure cell therapy to continue unchanged
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 ...
February 14, 2022, 10:29 am
Why are biocardia shares trading higher today?
The FDA has granted Breakthrough Device Designation for BioCardia Inc's BCDA cardiamp Cell Therapy...
February 3, 2022, 2:53 pm
Why are biocardia shares trading higher today?
The FDA has granted Breakthrough Device Designation for BioCardia Inc's BCDA cardiamp Cell Therapy...
February 3, 2022, 2:53 pm
Why are biocardia shares trading higher today?
The FDA has granted Breakthrough Device Designation for BioCardia Inc's BCDA cardiamp Cell Therapy...
February 3, 2022, 2:53 pm